X
Pharma Advancement
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    development of new antibiotics

    EMA guidance supports development of new antibiotics

    Thermo Fisher Scientific Announces Collaboration with Northeastern University to Advance Biopharmaceutical Characterization and Monitoring Workflows

    Commercial Success In New Biopharmaceutical Innovation Era

    Proteros and AstraZeneca Boost Collaboration Agreement

    Conver to wp

    AbbVie and Cugene Join Forces Concerning Autoimmune Disorders and Cancer

    Drug Imagent For Therapeutic Platform

    Japan Pharma Lobby Says-Price Scheme Is Causing Drug Lag

    Charles River and Valence Discovery Announce Strategic Partnership to Provide Clients with AI-Enabled Drug Design Capabilities

    Charles River and Valo Launch Logica, an Integrated AI-Powered Drug Discovery Solution to Rapidly Deliver Optimized Preclinical Assets

    AstraZeneca announces phase IV ASCENT trial of Tudorza Pressair in patients with COPD meets primary efficacy endpoint

    AstraZeneca announces plans for new strategic R&D centre and Alexion headquarters in Cambridge, Massachusetts

    Lynparza approved in the EU for BRCA-mutated metastatic pancreatic cancer

    Major Success Factors For Clinical Development Organizations

    ArisGlobal Expands LifeSphere Clinical Portfolio with Landmark Customer Wins in APAC & Middle East

    ArisGlobal Expands LifeSphere Clinical Portfolio with Landmark Customer Wins in APAC & Middle East

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    development of new antibiotics

    EMA guidance supports development of new antibiotics

    Thermo Fisher Scientific Announces Collaboration with Northeastern University to Advance Biopharmaceutical Characterization and Monitoring Workflows

    Commercial Success In New Biopharmaceutical Innovation Era

    Proteros and AstraZeneca Boost Collaboration Agreement

    Conver to wp

    AbbVie and Cugene Join Forces Concerning Autoimmune Disorders and Cancer

    Drug Imagent For Therapeutic Platform

    Japan Pharma Lobby Says-Price Scheme Is Causing Drug Lag

    Charles River and Valence Discovery Announce Strategic Partnership to Provide Clients with AI-Enabled Drug Design Capabilities

    Charles River and Valo Launch Logica, an Integrated AI-Powered Drug Discovery Solution to Rapidly Deliver Optimized Preclinical Assets

    AstraZeneca announces phase IV ASCENT trial of Tudorza Pressair in patients with COPD meets primary efficacy endpoint

    AstraZeneca announces plans for new strategic R&D centre and Alexion headquarters in Cambridge, Massachusetts

    Lynparza approved in the EU for BRCA-mutated metastatic pancreatic cancer

    Major Success Factors For Clinical Development Organizations

    ArisGlobal Expands LifeSphere Clinical Portfolio with Landmark Customer Wins in APAC & Middle East

    ArisGlobal Expands LifeSphere Clinical Portfolio with Landmark Customer Wins in APAC & Middle East

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home Europe

Novartis Foundation and partners launch of the of the Ho Chi Minh City Communities for Healthy Hearts Program in Vietnam

Yuvraj_pawp by Yuvraj_pawp
17th May 2016
in Europe, News
  • • Ho Chi Minh City Communities for Healthy Hearts Program is the second innovative healthcare model for hypertension        pioneered by the Novartis Foundation
  • • Screening and treatment shifts to the community via social entrepreneurs, while digital health technology empowers patients and health workers
  • • Nearly one quarter of the adult population in Vietnam has hypertension, but only 11% of these hypertensive patients have it under control
  • • Program partners include Ho Chi Minh City’s Provincial Health Department, PATH, the Hanoi School of Public Health and Lotus Impact

On the occasion of World Hypertension Day 2016, the Novartis Foundation and its partners, including the international nonprofit organization PATH, are announcing the launch of the Ho Chi Minh City Communities for Healthy Hearts Program, which is designed to improve health outcomes of adults with hypertension living in low-income households in urban Vietnam.
“I’m extremely pleased we are partnering with the Novartis Foundation to address this significant emerging healthcare challenge in Vietnam,” said PATH president and CEO Steve Davis. “We have leveraged our collective expertise in behavior change, health system strengthening, and technology solutions to create a truly innovative and people-centered healthcare model. We hope to see hypertension prevention and control made easy at the community level, for both health workers and patients.”

An international nonprofit organization, PATH saves lives, improves health and is a leader in global health innovation. PATH has a 35 year history of partnership in Vietnam.

Carried out in four districts in Ho Chi Minh City, covering a population of approximately two million people, Communities for Healthy Hearts will leverage new approaches to hypertension management by introducing social entrepreneurs to increase access points for cardiovascular health education and screening services. Additionally, the public and private health sectors will collaborate closely in this patient-centered approach to strengthen treatment and referral services. Digital health technology will empower patients in self-management and increase patient-to-provider contact. Learnings from this program will be evaluated to inform expansion of hypertension control efforts in Vietnam.

“We are excited to see our hypertension work extend to Vietnam through an innovative collaborative approach,” said Ann Aerts, Head of the Novartis Foundation. “As with our Community-based Hypertension Improvement Program (ComHIP) in Ghana, we hope to bring hypertension prevention and detection closer to patients to improve health outcomes and blood pressure control levels in urban settings in a way that is sustainable at scale.”

World Hypertension Day brings hypertension care and management into focus; complications from hypertension and high blood pressure account for 9.4 million deaths worldwide every year, this is equivalent to all infectious diseases combined.[1] Nearly 25% of the adult population in Vietnam has hypertension,[2] but less than half of them are aware of their condition. Of those diagnosed with hypertension, only 11% have it under control.[3] In urban areas of Vietnam the prevalence of hypertension is higher at 33%,[4] with Ho Chi Minh City being home to the largest urban population in the country.

The Novartis Foundation is collaborating on Communities for Healthy Hearts with the Ho Chi Minh City’s Provincial Health Department, PATH, the Hanoi School of Public Health, and Lotus Impact.

About the Novartis Foundation
The Novartis Foundation is a philanthropic organization pioneering innovative healthcare models that can have a transformational impact on the health of the poorest populations. We work hand-in-hand with our local and global partners to catalyze scalable and sustainable healthcare models to improve access and health outcomes, and to accelerate efforts to eliminate leprosy and malaria by focusing on interventions that aim to interrupt transmission. Everything we do is grounded in evidence and innovation, and our work is a continuous cycle of evaluation, adaptation and application. In 2015, the operational budget for the foundation was CHF 12 million and our programs reached 4.5 million people.

About Novartis
Novartis provides innovative healthcare solutions that address the evolving needs of patients and societies. Headquartered in Basel, Switzerland, Novartis offers a diversified portfolio to best meet these needs: innovative medicines, eye care and cost-saving generic pharmaceuticals. Novartis is the only global company with leading positions in these areas. In 2015, the Group achieved net sales of USD 49.4 billion, while R&D throughout the Group amounted to approximately USD 8.9 billion (USD 8.7 billion excluding impairment and amortization charges). Novartis Group companies employ approximately 118,000 full-time-equivalent associates. Novartis products are available in more than 180 countries around the world.
For questions about the site or required registration, please contact: media.relations@novartis.com

References
[1] Lim, SS, Vos, T, Flaxman, AD et al. A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012; 380: 2224-2260.
[2] Son, PT, Quang N., Viet NL., Khai PG, Wall S., Weinehall L., Bonita R., Byass P. Prevalence, awareness, treatment and control of hypertension in Vietnam – results from a national survey. J Hum Hypertension. 2012. 26(4): 268-80
[3] Pham, S. Hypertension in Vietnam: From community-based studies to a national targeted programme. Epidemiology and Global Health. Department of Public Health and Clinical Medicine. Umeå University, Sweden, and Vietnam National Heart Institute, Bach Mai Hospital & Hanoi Medical University. Umeå, Sweden: Umeå University; 2012.
[4] Son et al, 2012. Prevalence, awareness, treatment and control of hypertension in Vietnam – results from a national survey. Journal of Human Hypertension.

Tags: Europe
Previous Post

Chugai Pharmaceutical Co Ltd announced Efficacy of Actemra Subcutaneous Injection Confirmed in Dose Interval Reduction Study in Patients with Rheumatoid Arthritis

Next Post

Merck and Pfizer to Present Avelumab Data in Seven Different Cancers at ASCO Annual Meeting

Related Posts

FDA Experts Recommend Changing COVID Jab Formulation In Fall
Manufacturing

FDA Experts Recommend Changing COVID Jab Formulation In Fall

30th June 2022
Novartis to acquire The Medicines Company for USD 9.7 bn
Manufacturing

Novartis To Slash 8,000 Jobs To Save $1 Billion By 2024

30th June 2022
How Lag In African COVID-19 Jabs Slowed Its Once Rapid Pace
Manufacturing

How Lag In African COVID-19 Jabs Slowed Its Once Rapid Pace

27th June 2022
Australia Creates A Novel Stem Cell Production Technique
Manufacturing

Australia Creates A Novel Stem Cell Production Technique

27th June 2022
Novartis to acquire The Medicines Company for USD 9.7 bn
Manufacturing

Novartis Promises $250M For Tropical Illnesses, Malaria

27th June 2022
GSK commences phase III study of Benlysta and rituximab combination in systemic lupus erythematosus
Manufacturing

GSK Commits £1 Billion To Combat Infections In Poor Nations

27th June 2022
Next Post

Merck and Pfizer to Present Avelumab Data in Seven Different Cancers at ASCO Annual Meeting

Latest News

FDA Experts Recommend Changing COVID Jab Formulation In Fall
Manufacturing

FDA Experts Recommend Changing COVID Jab Formulation In Fall

30th June 2022
Novartis to acquire The Medicines Company for USD 9.7 bn
Manufacturing

Novartis To Slash 8,000 Jobs To Save $1 Billion By 2024

30th June 2022
How Lag In African COVID-19 Jabs Slowed Its Once Rapid Pace
Manufacturing

How Lag In African COVID-19 Jabs Slowed Its Once Rapid Pace

27th June 2022
Australia Creates A Novel Stem Cell Production Technique
Manufacturing

Australia Creates A Novel Stem Cell Production Technique

27th June 2022
Novartis to acquire The Medicines Company for USD 9.7 bn
Manufacturing

Novartis Promises $250M For Tropical Illnesses, Malaria

27th June 2022
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack

System

  • Search
  • Sitemap
  • RSS Feed

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In